

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

1
2 **Viral cultures for COVID-19 infectivity assessment – a systematic review (Update 3)**

3
4 Jefferson T¹; Spencer EA¹; Brassey J²; Heneghan C¹.

5
6 **Affiliations**

- 7 1. **Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe**
8 **Observatory Quarter, Oxford, OX2 6GG**
9 2. **Trip Database Ltd**

10
11
12 **Keywords:** Covid-19; mode of transmission, viral culture; symptom onset to test date; polymerase chain
13 reaction; SARS-CoV-2; infectivity.

14
15 Joint corresponding authors:

16 Jefferson (tom-jefferson@conted.ox.ac.uk)

17 Heneghan (Carl.heneghan@phc.ox.ac.uk)

18
19 **Summary**

20 **Objective** to review of the evidence from studies comparing SARS-CoV-2 culture, the best indicator of
21 current infection and infectiousness with the results of reverse transcriptase polymerase chain reaction (RT-
22 PCR).

23
24 **Methods** We searched LitCovid, medRxiv, Google Scholar and Google for Covid-19 for 'viral culture' or 'viral
25 replication' and associated synonyms up to 31st August 2020. We carried out citation matching and included
26 studies reporting attempts to culture or observe SARS-CoV-2 matching the with cutoffs for RT-PCR
27 positivity. One reviewer extracted data for each study and a second reviewer checked and edited the
28 extraction and summarised the narratively by sample: fecal, respiratory, environment or mixed.

29 Where necessary we wrote to corresponding authors of the included or background papers for additional
30 information. We assessed quality using a modified QUADAS 2 risk of bias tool.

31 This review is part of an [Open Evidence Review](#) on Transmission Dynamics of COVID-19. Summaries of the
32 included studies and the protocol (v1) are available at: [https://www.cebm.net/evidence-](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)

33 [synthesis/transmission-dynamics-of-covid-19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/). Searches are updated every 2 weeks. This is the third
34 version of this review that was first published on the 4th of August and updated on the 21st of August.

35 <https://www.medrxiv.org/content/10.1101/2020.08.04.20167932v2>

36
37 **Results** We included 25 studies reporting culturing or observing tissue invasion by SARS-CoV in sputum,
38 naso or oropharyngeal, urine, stool, blood and environmental samples from patients diagnosed with Covid-
39 19. The data are suggestive of a relation between the time from collection of a specimen to test, cycle

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

40 threshold (as a proxy for viral load) and symptom severity. The quality of the studies was moderate with lack
41 of standardised reporting. Ten studies reported that Ct values were significantly lower and log copies higher
42 in those with live virus culture. Nine studies reported no growth in samples based on a Ct cut-off value.
43 These values ranged from CT > 24 for no growth to Ct ≥ 34. Two studies report a strong relationship
44 between Ct value and ability to recover infectious virus and that the odds of live virus culture reduced by
45 33% for every one unit increase in Ct. A cut-off RT-PCR Ct > 30 was associated with non-infectious
46 samples. One study that analysed the NSP, N and E gene fragments of the PCR result reported different
47 cut-off thresholds depending on the gene fragment analysed. The duration of RNA shedding detected by
48 PCR was far longer compared to detection of live culture. Six out of eight studies reported RNA shedding for
49 longer than 14 days. Yet, Infectivity declines after day 8 even among cases with ongoing high viral loads. A
50 very small proportion of people re-testing positive after hospital discharge or with high Ct are likely to be
51 infectious.

52

53 **Conclusion**

54 Prospective routine testing of reference and culture specimens are necessary for each country involved in
55 the pandemic to establish the usefulness and reliability of PCR for Covid-19 and its relation to patients'
56 factors. Infectivity is related to the date of onset of symptoms and cycle threshold level.

57 A binary Yes/No approach to the interpretation RT-PCR unvalidated against viral culture will result in false
58 positives with segregation of large numbers of people who are no longer infectious and hence not a threat to
59 public health.

60

61 **Introduction**

62 The ability to make decisions on the prevention and management of COVID-19 infections rests on our
63 capacity to identify those who are infected and infectious. In the absence of predictive clinical signs or
64 symptoms¹, the most widely used means of detection is molecular testing using Reverse Transcriptase
65 quantitative Polymerase Chain Reaction (RT-qPCR)^{2,3}.

66 The test amplifies genomic sequences identified in samples. As it is capable of generating observable
67 signals from small samples, it is very sensitive. Amplification of genomic sequence is measured in cycle
68 thresholds (Ct). There appears to be a correlation between Ct values from respiratory samples, symptom
69 onset to test (STT) date and positive viral culture. The lower the Ct value (as a proxy for total viral load) and
70 the shorter the STT, the higher the infectivity potential⁴.

71 Whether probing for sequences or whole genomes⁵, in the diagnosis of Covid-19 a positive RT-qPCR cannot
72 tell you whether the person is infectious or when the infection began, nor the provenance of the genetic
73 material. Very early in the COVID-19 outbreak it was recognised that cycle threshold values may be a proxy
74 for quantitative measure of viral load, but correlation with clinical progress and transmissibility was not yet
75 known⁶. A positive result indicates that a person has come into contact with the genomic sequence or some
76 other viral antigen at some time in the past. However, presence of viral genome on its own is not sufficient
77 proof of infectivity and caution is needed when evaluating the infectivity of specimens simply based on the
78 detection of viral nucleic acids⁵. In addition, viral genomic material can be still be present weeks after
79 infectious viral clearance.⁷ Like all tests, RT-qPCR requires validation against a gold standard. In this case
80 isolation of a whole virion (as opposed to fragments) and proof that the isolate is capable of replicating its
81 progeny in culture cells is the closest we are likely to get to a gold standard.⁸

82 Our [Open Evidence Review](#) of transmission modalities of SARS CoV-2 identified a low number of studies
83 which have attempted viral culture. There are objective difficulties in doing such cultures such as the
84 requirement for a level III laboratory, avoidance of contamination, time and the quality of the specimens as
85 well as financial availability of reagents and culture media to rule out the presence of other pathogens.
86 As viral culture represents the best indicator of infection and infectiousness, we set out to review the
87 evidence on viral culture compared to PCR, and report the results of those studies attempting viral culture
88 regardless of source (specimen type) of the sample tested.

89

90 **Methods**

91 We conducted an initial search using LitCovid, medRxiv, Google Scholar and Google for Covid-19 using the
92 terms 'viral culture' or 'viral replication' and associated synonyms. Searches were last updated 31st August
93 2020. We reviewed the results for relevance and the searches were stopped when no new relevant articles
94 were apparent. For articles that looked particularly relevant, citation matching was undertaken and relevant
95 results were identified.

96 We included studies reporting attempts to culture SARS-CoV-2 and those which also estimated the
97 infectiousness of the isolates or observed tissue invasion by SARS CoV-2. One reviewer extracted data for
98 each study and a second review checked and edited the extraction. We tabulated the data and summarised
99 data narratively by mode of sample: fecal, respiratory, environment or mixed.

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

100 Where necessary we wrote to corresponding authors of the included or background papers for additional
101 information. We assessed quality using a modified QUADAS 2 risk of bias tool. We simplified the tool as the
102 included studies were not designed as primary diagnostic accuracy studies.⁹
103 This review is part of an [Open Evidence Review](#) on Transmission Dynamics of COVID-19. Summaries of the
104 included studies and the protocol (v1) are available at: [https://www.cebm.net/evidence-](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)
105 [synthesis/transmission-dynamics-of-covid-19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/). Searches are updated every 2 weeks.

106
107 This is the third update of this review that has seen nine studies added in three weeks.

108

109 **Results**

110 We identified 144 articles of possible interest and after screening full texts included 25 (see PRISMA¹⁰ flow
111 chart - Figure 1). We identified one unpublished study which was not included as no permission to do so was
112 given by the authors. The salient characteristics of each included study are shown in Table 1.

113 All included studies were case series of **moderate quality** (Table 2. Quality of included studies). We could
114 not identify a protocol for any of the studies. All the included studies had been either published or were
115 available as preprints. All had been made public in 2020. We received four responses from authors
116 regarding clarifying information (see Acknowledgments).

117

118 **Studies using fecal samples**

119 Five studies used fecal samples which were positive for SARS-CoV-2 based on RT-PCR result¹¹⁻¹⁵ and
120 reported achieving viral isolation, and one laboratory study¹⁶ found that SARS-CoV-2 infected human small
121 intestinal organoids. A further study visually identified virions in colon tissue.¹⁷

122

123 **Studies using respiratory samples**

124 Fourteen studies on respiratory samples reported achieving viral isolation. One study assessed 90
125 nasopharyngeal samples and cultured 26 of the samples, and positive cultures were only observed up to day
126 eight post symptom onset;⁴ another study obtained 31 cultures from 46 nasopharyngeal and oropharyngeal
127 samples;¹⁸ while 183 nasopharyngeal and sputum samples produced 124 cases in which a cytopathic effect
128 was observed although the denominator of samples taken was unclear¹⁹. Another study in health care
129 workers in UK hospitals isolated one SARS Cov-2 from nineteen specimens in a situation of low viral
130 circulation.²⁰

131 Two more studies reported a clear correlation between symptoms onset, date of sampling, Ct and likelihood
132 of viral culture.^{21 22}

133

134 L'Huillier and colleagues²³ sampled nasopharyngeal swabs in 638 patients aged less than 16 years in a
135 Geneva Hospital: 23 (3.6%) tested positive for SARS CoV-2 - median age of 12 years and 12 (52% were
136 culture positive). The Ct was around 28 for the children whose samples grew viable viruses. Gniazdowski²⁴
137 probably assessed 161 nasopharyngeal specimens. A positive culture was associated with Ct values of 18.8
138 ± 3.4. Infectious viral shedding occurred in specimens (a Ct ≥ 23 yielded 8.5% of virus isolates).

139

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

140 Basile and colleagues 25 found a culture positivity rate of 24%, which was significantly more likely positive
141 in ICU patients compared with other inpatients or outpatients.

142 A report by the Korean Centres for Disease Control failed to grow live viruses from 108 respiratory samples
143 from “re-positives” i.e. people who had tested positive after previously testing negative²⁶

144
145

146 **Studies using environmental samples**

147 Two possible positive cultures were obtained from 95 environmental samples in one study that assessed the
148 aerosol and surface transmission potential of SARS-CoV-2²⁷. Zhou and colleagues reported on samples
149 taken from seven areas of a large London hospital. Despite apparent extensive air and surface
150 contamination of the hospital environment, no infectious samples were grown²⁸. For air samples, 2/31
151 (6.4%) were positive and 12/31 (39%) suspect for SARS-CoV-2 RNA but no virus was cultured. Similarly,
152 91 of 218 surface samples were suspect (42%) or 23 positive (11%) for SARS-CoV-2 RNA but no virus was
153 cultured. The authors noted that a cut-off RT-PCR Ct > 30 was associated with non-infectious specimens.

154

155 **Mixed sources**

156 Seven studies reported viral culture from mixed sources. Using 60 samples from 50 cases of Covid-19, viral
157 culture was achieved from 12 oropharyngeal, nine nasopharyngeal and two sputum samples⁵. Jeong et al¹¹
158 who reported isolation live virus from a stool sample also reported that from of an unreported number of
159 nasopharyngeal, oropharyngeal, saliva, sputum and stool samples, one viral culture was achieved: ferrets
160 inoculated with these samples became infected; SARS-CoV-2 was isolated from the nasal washes of the two
161 urine-treated ferrets and one stool-treated ferret¹¹. An unreported number of samples from saliva, nasal
162 swabs, urine, blood and stool collected from nine Covid-19 patients produced positive cultures and a
163 possible specimen stool culture²⁹. One study showed that from nine nasopharyngeal, oropharyngeal, stool,
164 serum and urine samples, all nine were culturable, including two from non-hospitalised Covid-19 patients³⁰.
165 Yao and colleagues cultured viable viral isolates from seven sputum samples, three stool samples and one
166 nasopharyngeal sample of 11 patient aged 4 months to 71 years, indicating that the SARS-CoV-2 is capable
167 of replicating in stool samples as well as sputum and the nasopharynx.³¹ All samples had been taken within
168 5 days of symptom onset. The authors also report a relationship between viral load (copy thresholds) and
169 cytopathic effect observed in infected culture cells.³²

170 Kim and colleagues reported no viral growth from and unclear number of serum, urine and stool samples
171 despite collection very soon after admission³³. Lu and colleagues also reported no viral growth, however
172 their specimens were from 87 cases tested “re-positive”.³⁴

173

174 **Blood cultures**

175 In one study by Andersson³⁵ et al 20 RT-PCR positive serum samples were selected at random from a
176 Covid-19 sample bank, representing samples from 12 individual patients (four individuals were represented
177 at two timepoints), collected at 3 to 20 days following onset of symptoms. None of the 20 serum samples
178 produced a viral culture

179

180 **Duration of viral shedding**

181 Eight studies report on the duration of viral shedding as assessed by PCR for SARS-CoV-2 RNA^{4 11 17 13 29 30}
182^{13 22}. The minimum duration of RNA shedding detected by PCR was seven days reported in Bullard, the
183 maximum duration of shedding was 35 days after symptom onset in Qian. Six out of eight studies reported
184 RNA shedding for longer than 14 days (see Table 3).

185

186 **Duration of live viral culture detection**

187 The duration of live viral culture detection was much shorter than viral shedding. Wölfel et al²⁹ reported that
188 virus could not be isolated from samples taken after day 8 even among cases with ongoing high viral loads
189 of approximately 105 RNA copies/mL. Bullard et al similarly reported that SARS-CoV-2 Vero cell infectivity of
190 respiratory samples from SARS-CoV-2 positive individuals was only observed for RT-PCR Ct < 24 and
191 symptom onset to test of < 8 days⁴. Singanayagam and colleagues²² reported the median duration of virus
192 shedding as measured by viral culture was 4 days (Inter Quartile Range: 1 to 8)²².

193

194 **The relationship between RT-PCR results and viral culture of SARS-CoV-2**

195 Fourteen studies attempted to quantify the relationship between cycle threshold (Ct) and likelihood of
196 culturing live virus^{4 5 12 19 13 30 29 31 22 21 20 23-25}. Table 4 shows that five studies analysed the relationship
197 between Ct values and live viral culture and five quantified the mean log copies of detected virus and live
198 culture. All ten reported that Ct were significantly lower and log copies were significantly higher in those with
199 live virus culture. Nine studies reported no growth in samples based on a Ct cut-off value. These values
200 ranged from CT > 24 for no growth⁴ to Ct ≥ 34^{4 19}. Singanayagam et al²² reported the estimated probability
201 of recovery of virus from samples with Ct > 35 was 8.3% (95% CI: 2.8%–18.4%). All those above the Ct
202 threshold of 35 (n=5) with live culture were symptomatic.

203

204 Huang analysed the NSP, N and E gene fragments of the PCR result, which reported different cut-off
205 thresholds depending on the gene fragment analysed⁵. No growth was found for the Nsp 12 fragment at Ct >
206 31.47, whereas the value was higher for the N gene fragment at >35.2.

207

208 Bullard et al⁴ reported a reduction in the odds ratio for culturing live virus of 0.64 for every one unit increase
209 in Ct (95%CI 0.49 to 0.84, p<0.001). Similar to Bullard and colleagues, Singanayagam²² reported a strong
210 relationship between Ct value and ability to recover infectious virus: estimated OR of recovering infectious
211 virus decreased by 0.67 for each unit increase in Ct value (95% CI: 0.58–0.77). This value is very close to
212 that of other empirical studies (an increased Ct of 0.58 per day since symptoms started)³⁶

213

214

215 **Discussion**

216 Society is attempting to interrupt transmission of SARS-CoV 2 by identifying and isolating those who are sick
217 and those who are infectious. As there are no Covid-19-specific mass treatments or preventive measures,
218 such a strategy relies on our capability of identifying such persons with a reasonable amount of certainty to
219 avoid isolation of people who pose little threat to the public health. An increasing body of evidence shows

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

220 that such identification cannot be accurately achieved through the simplistic division of those who test
221 positive and who do not on the basis of the results of RT-PCR. The sensitivity and specificity of RT-PCR
222 needs comparing to the gold standard of infectiousness: the capacity to grow live virus from a specimen.
223

224 The authors of the studies in our review have attempted and successfully achieved culture of SARS-CoV-2
225 in the laboratory, using a range of respiratory, fecal or environmentally collected samples. However the
226 simplistic dichotomous division into positive/negative is sufficient to accurately identify infectiousness. The
227 evidence shows that there is a positive relationship between lower cycle count threshold, viral culturability
228 and date of symptom onset. Nowhere can this be seen as clearly as in the two studies assessing the
229 infectiousness of “re-positives”, i.e. those COVID-19 cases who had been discharged from hospital after
230 testing negative repeatedly and then testing positive after discharge: Lu 2020³⁴, Korean CDC²⁶.

231 In a very tightly designed and argued study Lu and colleagues tested four hypotheses for the origin of “re-
232 positives” 2020³⁴. After discarding the first two (re-infection and latency) on the basis of their evidence, they
233 reached the conclusions that the most plausible explanations were contamination of the sample by
234 extraneous material or identification in the sample of minute and irrelevant particles of SARS-Cov-2 long
235 cleared by the immune system.

236 Both explanations fit the facts, the others do not. It is very likely that a huge expansion in testing capability
237 requires training protocols and precautions to avoid poor laboratory practice which are simply not possible in
238 the restricted times of a pandemic. We equally know that weak positives (those with high Ct) are unlikely to
239 be infectious, as a whole live virus is the prime requirement for transmission, not the fragments identified by
240 PCR.

241 The purpose of viral testing is to assess the relation of the micro-organism and hazard to humans, i.e. its
242 clinical impact on the individual providing the sample for primary care and the risk of transmission to others
243 for public health. PCR on its own is unable to provide such answers. When interpreting the results of RT-
244 PCR it is important to take into consideration the clinical picture, the cycle threshold value and the number of
245 days from symptom onset to test (STT)³⁷. Several of our included studies assessed the relationship of these
246 variables and there appears to be a time window during which shedding is at its highest with low cycle
247 threshold and higher possibility of culturing a live virus. We propose that further work should be done on this
248 with the aim of constructing a calibrating algorithm for PCR which are likely to detect infectious patients. PCR
249 should be continuously calibrated against a reference culture in Vero cells in which cytopathic effect has
250 been observed⁴. Confirmation of visual identification using methods, such as an immunofluorescence assay
251 may also be relevant for some virus types⁸. Henderson and colleagues have called for a multicenter study
252 of all currently manufactured SARS-CoV-2 nucleic acid amplification tests to correlate the cycle threshold
253 values on each platform for patients who have positive and negative viral cultures. Calibration of assays
254 could then be done to estimate virus viability from the cycle threshold with some certainty.³⁸

255 Ascertainment of infectiousness is all the more important as there is good evidence of viral RNA persistence
256 across a whole range of different viral RNA disease with little or no infectivity in the post infectious phase on
257 MERS³⁹, measles⁴⁰, other coronaviridae⁴¹, HCV and a variety of animal RNA viruses⁴¹. In one COVID-19
258 (former) case this persisted until day 78 from symptoms onset with a very high Ct³⁶ but no culture growth,
259 showing its lack of infectiousness.

260

261 We are unsure whether SARS CoV-2 methods of cell culture have been standardised. Systems can vary
262 depending upon the selection of the cell lines; the collection, transport, and handling of and the maintenance
263 of viable and healthy inoculated cells⁴². We therefore recommend that standard methods for culture should
264 be urgently developed. If identification of viral infectivity relies on visual inspection of cytopathogenic effect,
265 then a reference culture of cells must also be developed to test recognition against infected cells. Viral
266 culture may not be appropriate for routine daily results, but specialized laboratories should rely on their own
267 ability to use viruses as controls, perform complete investigations when needed, and store representative
268 clinical strains whenever possible⁴². In the absence of culture, ferret inoculation of specimen washings and
269 antibody titres could also be used. It may be impossible to produce a universal Cycle threshold value as this
270 may change with circumstances (e.g. hospital, community, cluster and symptom level), laboratory methods⁴³
271 and the current evidence base is thin.

272

273 We suggest the WHO produce a protocol to standardise the use and interpretation of PCR and routine use
274 of culture or animal model to continuously calibrate PCR testing, coordinated by designated [Biosafety Level](#)
275 [III laboratory](#) facilities with inward directional airflow⁴⁴. Further studies with standardised methods⁴³ and
276 reporting are needed to establish the magnitude and reliability of this association.

277

278 The results of our review are similar to those of the living review by Cevick and colleagues⁴⁵. Although the
279 inclusion criteria are narrower than ours, the authors reviewed 79 studies on the dynamics, load and
280 shedding for SARS CoV-1, MERS and SARS CoV-2 from symptoms onset. They conclude that although
281 SARS-CoV-2 RNA shedding in respiratory (up to 83 days) and stool (35 days) can be prolonged, duration of
282 viable virus is relatively short-lived (up to a maximum of 8 days from symptoms onset). Results that are
283 consistent with Bullard et al who found no growth in samples with a cycle threshold greater than 24 or when
284 symptom onset was greater than 8 days, and Wölfel [et al](#)²⁹ who reported that virus could not be isolated
285 from samples taken after day 8 even among cases with ongoing high viral loads.

286

287 The evidence is increasingly pointing to the probably of culturing live virus is related to the amount of viral
288 RNA in the sample and, therefore, inversely related to the cycle threshold. Thus, blanket detection of viral
289 RNA cannot be used to infer infectiousness. Length of excretion is also linked to age, male gender and
290 possibly use of steroids and severity of illness. Of note, live virus excretion peaked later in SARS CoV-1 and
291 MERS⁴⁵

292

293 The limits of our review are the low number of studies of relatively poor quality with lack of standardised
294 reporting and lack of gold testing for each country involved in the pandemic. We plan to keep updating this
295 review with emerging evidence.

296

297 **Conclusion**

298

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

299 The current data are suggestive of a relation between the time from collection of a specimen to test, copy
300 threshold, and symptom severity, but the quality of the studies limits firm conclusions to be drawn. We
301 recommend that a uniform international standard for reporting of comparative SARS-CoV-2 culture with
302 index test studies be produced. Particular attention should be paid to the relationship between the results of
303 testing, clinical conditions and the characteristics of the source patients, description of flow of specimens and
304 testing methods. Extensive training of operators and avoidance of contamination should take place on the
305 basis of fixed and internationally recognised protocols. Defining cut off levels predictive of infectivity should
306 be feasible and necessary for diagnosing viral respiratory infections using molecular tests⁴⁶.
307 We will contact the corresponding authors of the 11 studies correlating ct with likelihood of culture to assess
308 whether it is possible to aggregate data and determine a firm correlation to aid decision making.
309
310

311 **Acknowledgments**

312 Drs Susan Amirian, Siyuan Ding, Long Rong and Sravanthi Parasato provided additional information for this
313 brief. Dr Maryanne DeMasi helped with reference identification.
314

315 **Funding**

316 The review was partly funded by NIHR Evidence Synthesis Working Group project 380 and supported by the
317 Maria and David Willets foundation.
318

319 **Disclaimer:** The article has not been peer-reviewed. The views expressed in this commentary represent the
320 views of the authors and not necessarily those of the host institution, the NHS, the NIHR, or the Department
321 of Health and Social Care. The views are not a substitute for professional medical advice. It will be regularly
322 updated see the evidence explorer at [https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)
323 [covid-19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/) for regular updates to the evidence summaries and briefs.
324

325 **Data Availability**

326 All data included in the review are from publications or preprints. All extractions sheets with direct links to the
327 source paper are available from [https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)
328 [19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)
329

330 **Authors:**

331 Tom Jefferson is a Senior Associate Tutor and Honorary Research Fellow, Centre for Evidence-Based
332 Medicine, University of Oxford. Disclosure statement is here
333

334 Elizabeth Spencer is Epidemiology and Evidence Synthesis Researcher at the Centre for Evidence-Based
335 Medicine. (Bio and disclosure statement here)
336

337 Jon Brassey is the Director of Trip Database Ltd, Lead for Knowledge Mobilisation at Public Health Wales
338 (NHS) and an Associate Editor at the BMJ Evidence-Based Medicine.

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

339 Carl Heneghan is Professor of Evidence-Based Medicine, Director of the Centre for Evidence-Based
340 Medicine and Director of Studies for the Evidence-Based Health Care Programme. (Full bio and disclosure
341 statement here)

342 This work is licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](#).

343

344

345 References

- 346 1. Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19:
347 systematic review and critical appraisal. *BMJ* 2020;369:m1328. doi: 10.1136/bmj.m1328
- 348 2. Transmission of SARS-CoV-2: implications for infection prevention precautions. Scientific brief.
349 . 2020
- 350 3. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16-24 February 2020.
351 2020
- 352 4. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *LID -*
353 *10.1093/cid/ciaa638* [doi] *LID - ciaa638*. (1537-6591 (Electronic))
- 354 5. Huang C-G, Lee K-M, Hsiao M-J, et al. Culture-Based Virus Isolation To Evaluate Potential Infectivity of
355 Clinical Specimens Tested for COVID-19. *J Clin Microbiol* 2020;58(8):e01068-20. doi:
356 10.1128/jcm.01068-20
- 357 6. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected
358 With SARS-CoV-2 in Singapore. (1538-3598 (Electronic))
- 359 7. Atkinson B, Petersen E. SARS-CoV-2 shedding and infectivity. *The Lancet* 2020;395(10233):1339-40. doi:
360 10.1016/S0140-6736(20)30868-0
- 361 8. Hematian A, Sadeghifard N, Mohebi R, et al. Traditional and Modern Cell Culture in Virus Diagnosis.
362 *Osong public health and research perspectives* 2016;7(2):77-82. doi: 10.1016/j.phrp.2015.11.011
363 [published Online First: 2016/01/08]
- 364 9. Whiting PF, Rutjes Aw Fau - Westwood ME, Westwood Me Fau - Mallett S, et al. QUADAS-2: a revised
365 tool for the quality assessment of diagnostic accuracy studies. (1539-3704 (Electronic))
- 366 10. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-
367 analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4(1):1-1. doi: 10.1186/2046-4053-4-1
- 368 11. Jeong HW, Kim S-M, Kim H-S, et al. Viable SARS-CoV-2 in various specimens from COVID-19 patients.
369 *Clin Microbiol Infect* 2020:S1198-743X(20)30427-4. doi: 10.1016/j.cmi.2020.07.020
- 370 12. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. (1538-
371 3598 (Electronic))
- 372 13. Xiao F SJ, Xu Y, Li F et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. 2020 doi:
373 <https://doi.org/10.3201/eid2608.200681>
- 374 14. Yong Z, Cao C, Shuangli Z, et al. Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-
375 Confirmed Case of the Coronavirus Disease 2019 (COVID-19). *China CDC Weekly* 2020;2(8):123-24.
376 doi: 10.46234/ccdcw2020.033
- 377 15. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. (1528-0012
378 (Electronic))
- 379 16. Lamers MA-O, Beumer JA-O, van der Vaart JA-O, et al. SARS-CoV-2 productively infects human gut
380 enterocytes. (1095-9203 (Electronic))
- 381 17. Qian Q, Fan L, Liu W, et al. Direct evidence of active SARS-CoV-2 replication in the intestine. *Clinical*
382 *Infectious Diseases* 2020 doi: 10.1093/cid/ciaa925

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

- 383 18. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a
384 Skilled Nursing Facility. *New England Journal of Medicine* 2020;382(22):2081-90. doi:
385 10.1056/NEJMoa2008457
- 386 19. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management
387 tool for discharge of SARS-CoV-2 patients from infectious disease wards. *European Journal of*
388 *Clinical Microbiology & Infectious Diseases* 2020;39(6):1059-61. doi: 10.1007/s10096-020-03913-9
- 389 20. Brown CS, Clare K, Chand M, et al. Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England.
390 *Journal of Infection* 2020;81(3):427-34. doi: 10.1016/j.jinf.2020.06.069
- 391 21. Perera RAPM, Tso E, Tsang OTY, et al. SARS-CoV-2 Virus Culture and Subgenomic RNA for Respiratory
392 Specimens from Patients with Mild Coronavirus Disease. *Emerging Infectious Disease journal*
393 2020;26(11) doi: 10.3201/eid2611.203219
- 394 22. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle
395 threshold values in cases of COVID-19, England, January to May 2020. *Eurosurveillance*
396 2020;25(32):2001483. doi: <https://doi.org/10.2807/1560-7917.ES.2020.25.32.2001483>
- 397 23. L'Huillier A, Torriani G, Pigny F, et al. Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic
398 Neonates, Children, and Adolescents. *Emerging Infectious Disease journal* 2020;26(10) doi:
399 10.3201/eid2610.202403
- 400 24. Gniazdowski V, Morris CP, Wohl S, et al. Repeat COVID-19 Molecular Testing: Correlation with Recovery
401 of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity. *medRxiv*
402 2020:2020.08.05.20168963. doi: 10.1101/2020.08.05.20168963
- 403 25. Basile K, McPhie K, Carter I, et al. Cell-based culture of SARS-CoV-2 informs infectivity and safe de-
404 isolation assessments during COVID-19. *medRxiv* 2020:2020.07.14.20153981. doi:
405 10.1101/2020.07.14.20153981
- 406 26. Prevention. KCfDCa. Findings from investigation and analysis of re-positive cases 2020
- 407 27. Santarpia JL, Rivera DN, Herrera V, et al. Aerosol and Surface Transmission Potential of SARS-CoV-2.
408 *medRxiv* 2020:2020.03.23.20039446. doi: 10.1101/2020.03.23.20039446
- 409 28. Zhou J, Otter JA, Price JR, et al. Investigating SARS-CoV-2 surface and air contamination in an acute
410 healthcare setting during the peak of the COVID-19 pandemic in London. *Clinical Infectious Diseases*
411 2020 doi: 10.1093/cid/ciaa905
- 412 29. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-
413 2019. *Nature* 2020;581(7809):465-69. doi: 10.1038/s41586-020-2196-x
- 414 30. Kujawski SA, Wong KK, Collins JP, et al. Clinical and virologic characteristics of the first 12 patients with
415 coronavirus disease 2019 (COVID-19) in the United States. *Nature Medicine* 2020;26(6):861-68. doi:
416 10.1038/s41591-020-0877-5
- 417 31. Yao H, Lu X, Chen Q, et al. Patient-derived mutations impact pathogenicity of SARS-CoV-2. *medRxiv*
418 2020:2020.04.14.20060160. doi: 10.1101/2020.04.14.20060160
- 419 32. Yuan CA-O, Zhu H, Yang YA-OX, et al. Viral loads in throat and anal swabs in children infected with SARS-
420 CoV-2. (2222-1751 (Electronic))
- 421 33. Kim JA-O, Kim HA-O, Lee EA-O, et al. Detection and Isolation of SARS-CoV-2 in Serum, Urine, and Stool
422 Specimens of COVID-19 Patients from the Republic of Korea. (2210-9099 (Print))
- 423 34. Lu J, Peng J, Xiong Q, et al. Clinical, immunological and virological characterization of COVID-19 patients
424 that test re-positive for SARS-CoV-2 by RT-PCR. *EBioMedicine* 2020;59 doi:
425 10.1016/j.ebiom.2020.102960
- 426 35. Andersson M, Arancibia - Carcamo CV, Auckland K, et al. SARS-CoV-2 RNA detected in blood samples
427 from patients with COVID-19 is not associated with infectious virus. *medRxiv*
428 2020:2020.05.21.20105486. doi: 10.1101/2020.05.21.20105486
- 429 36. Lesho E, Reno L, Newhart D, et al. Temporal, Spatial, and Epidemiologic Relationships of SARS-CoV-2
430 Gene Cycle Thresholds: A Pragmatic Ambi-directional Observation. *Clinical Infectious Diseases* 2020
431 doi: 10.1093/cid/ciaa1248
- 432 37. Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. *Clinical*
433 *Infectious Diseases* 2020 doi: 10.1093/cid/ciaa619

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review


- 434 38. Henderson DK, Weber DJ, Babcock H, et al. The perplexing problem of persistently PCR-positive
435 personnel. *Infection Control & Hospital Epidemiology* 2020;1-2. doi: 10.1017/ice.2020.343
436 [published Online First: 2020/07/20]
- 437 39. Bin SY, Heo JY, Song M-S, et al. Environmental Contamination and Viral Shedding in MERS Patients
438 During MERS-CoV Outbreak in South Korea. *Clinical Infectious Diseases* 2015;62(6):755-60. doi:
439 10.1093/cid/civ1020
- 440 40. Lin W-HW, Kouyos RD, Adams RJ, et al. Prolonged persistence of measles virus RNA is characteristic of
441 primary infection dynamics. *Proceedings of the National Academy of Sciences* 2012;109(37):14989-
442 94. doi: 10.1073/pnas.1211138109
- 443 41. Owusu M, Annan A, Corman VM, et al. Human Coronaviruses Associated with Upper Respiratory Tract
444 Infections in Three Rural Areas of Ghana. *PLOS ONE* 2014;9(7):e99782. doi:
445 10.1371/journal.pone.0099782
- 446 42. Hodinka RL. Point: is the era of viral culture over in the clinical microbiology laboratory? *J Clin Microbiol*
447 2013;51(1):2-4. doi: 10.1128/JCM.02593-12 [published Online First: 2012/10/10]
- 448 43. Binnicker MA-O. Challenges and Controversies Related to Testing for COVID-19. LID - JCM.01695-20 [pii]
449 LID - 10.1128/JCM.01695-20 [doi]. (1098-660X (Electronic))
- 450 44. Laboratory support for COVID-19 in the EU/EEA. Testing for SARS-CoV-2 virus European Centre for
451 Disease Prevention and Control. 2020
- 452 45. Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of
453 viral shedding and infectiousness: a living systematic review and meta-analysis. *medRxiv*
454 2020:2020.07.25.20162107. doi: 10.1101/2020.07.25.20162107
- 455 46. Jansen RR, Wieringa J, Koekkoek SM, et al. Frequent Detection of Respiratory Viruses without
456 Symptoms: Toward Defining Clinically Relevant Cutoff Values. *J Clin Microbiol* 2011;49(7):2631-36.
457 doi: 10.1128/jcm.02094-10
- 458 47. Kim J-M, Kim HM, Lee EJ, et al. Detection and Isolation of SARS-CoV-2 in Serum, Urine, and Stool
459 Specimens of COVID-19 Patients from the Republic of Korea. *Osong Public Health Res Perspect*
460 2020;11(3):112-17. doi: 10.24171/j.phrp.2020.11.3.02
- 461

462

Figure 1 - PRISMA 2009 Flow Diagram

463

464



Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| Serial | Study | Samples (source) | Samples (n) [SST] | Culture methods | Culture Positive | Additional notes |
|--------|--------------------------------------|--|--|--|--|--|
| 1. | Bullard ⁴ | Nasopharyngeal (NP) or endotracheal (ETT) from COVID-19 patients (mean age 45 years) | 90 [0 to 7 days] | NP swabs and ETT specimens in viral transport media were stored at 4°C for 24-72 hours until they were tested for the presence of SARS-CoV-2 RNA using real-time RT-PCR targeting a 122nt portion of the Sarbecovirus envelope gene (E gene). Dilutions were placed onto the Vero cells in triplicate and incubated at 37°C with 5% CO2 for 96 hours. Following incubation of 4 days, cytopathic effect was evaluated under a microscope and recorded. | 26 | The range of symptoms onset to negative PCT was 21 days. Within this period, positive cultures were only observed up to day 8 post symptom onset |
| 2. | Huang ⁵ | Oropharyngeal (OP) or nasopharyngeal (NP) swabs, or sputum (SP) | 60 specimens from 50 cases [3,4 days mean but see table 1 for freeze thaw cycles delays] | SARS-CoV-2 cDNA was prepared using RNA extracted from the specimens of the first patient with confirmed COVID-19. RT was performed using the MMLV Reverse transcription kit. All procedures for viral culture were conducted in a biosafety level-3 facility. Vero-E6 and MK-2 (ATCC) cells were maintained in a virus culture medium and the cells were maintained in a 37°C incubator with daily observations of the cytopathic effect. | 12 OP, 9 NP and two from SP specimens were culturable | Specimens with high copy numbers of the viral genome, indicative of higher viral load, were more likely to be culturable. |
| 3. | Jeong ¹¹ | Naso/oropharyngeal swabs, saliva, urine, and stool | 5 patients | Specimens positive by qPCR were subjected to virus isolation in Vero cells. Urine and stool samples were inoculated intranasally in ferrets and they evaluated the virus titers in nasal washes on 2, 4, 6, and 8 days post-infection (dpi). Immunofluorescence antibody assays were also done. | Naso/ oropharyngeal saliva, urine and stool Samples were collected between days 8 to 30 of the clinical course. Viable SARS-CoV-2 was isolated from 1 naso / oropharyngeal swab. Ferrets inoculated with patient urine or stool were infected. | Viral loads in urine, saliva, and stool samples were almost equal to or higher than those in naso / oropharyngeal swabs. After symptom resolution, patients shed viable virus in their saliva and urine up to day 15 of illness. |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | | |
|----|---|---|--|---|---|---|
| | | | | | SARS-CoV-2 was isolated from the nasal washes of the 2 urine-treated ferrets and one stool-treated ferret | |
| 4. | Qian ¹⁷ | Rectal tissue obtained from a surgical procedure was available. | 1 [1 to 3 days post op] | Ultrathin sections of tissue fixed in epoxy resin on formvar-coated copper grids were observed under electron microscope under 200kV. Immunohistochemical staining was used to establish expression and distribution of SARS-CoV-2 antigen. | 1 | No culture performed. Visualisation of virions in rectal tissue and detection of SARS-CoV-2 antigen in the rectal tissue. |
| 5. | Wang ¹² | Bronchoalveolar fluid, sputum, feces, blood, and urine specimens from hospital in-patients with COVID-19 | 4 fecal samples with sufficiently high copy numbers from 1,070 specimens collected from 205 patients with COVID-19 (mean age of 44 years and 68% male [1 to 3 days from hospital admission]) | rRT-PCR targeting the open reading frame 1ab gene of SARS-CoV-2; cycle threshold values of rRT-PCR were used as indicators of the copy number of SARS-CoV-2 RNA in specimens with lower cycle threshold values corresponding to higher viral copy numbers. A cycle threshold value less than 40 was interpreted as positive for SARS-CoV-2 RNA. Four SARS-CoV-2 positive fecal specimens with high copy numbers were cultured, and then electron microscopy was performed to detect live virus. | 4 viewed by electron microscope | The details of how the 4 samples were cultured were not reported. The patients did not have diarrhoea. |
| 6. | Xiao F, Sun J ¹³ | Serial feces samples collected from 28 hospitalised COVID-19 patients: 3 samples from 3 RNA-positive patients were tested for possible viral culture. | 3, one patient admitted day 7 post onset | Inoculation of Vero 6 cells. Cycle threshold values for the fecal sample were 23.34 for the open reading frame 1ab gene and 20.82 for the nucleoprotein gene. A cytopathic effect was visible in Vero E cells 2 days after a second-round passage. The researchers negatively stained culture supernatant and visualized by transmission electron microscopy. Viral particles that were visible were spherical and had distinct surface spike protein projections, consistent | 2/3 (infectious virus was present in faeces from two cases) | Selection of samples is not entirely clear. |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | | |
|-----|---|--|---|--|--|--|
| | | | | with a previously published SARS-CoV2 image. | | |
| 7. | Arons ¹⁸ | nasopharyngeal and oropharyngeal swabs | 46 rRT-PCR–positive specimens [For asymptomatic median 4 days, Ct 23.1] | All rRT-PCR positive samples shipped to USA CDC for viral culture using Vero-CCL-81 cells. Cells showing cytopathic effects were used for SARS-CoV-2 rRT-PCR to confirm isolation and viral growth in culture. | 31 [no relation to symptoms presence. Culturable virus isolated from 6 days before to 9 days after symptom onset] | |
| 8. | La Scola ¹⁹ | Naso pharyngeal swabs or sputum samples | 183 (4384 samples from 3466 patients) [not reported] | From 1,049 samples, 611 SARS-CoV-2 isolates were cultured. 183 samples testing positive by RT-PCR (9 sputum samples and 174 nasopharyngeal swabs) from 155 patients, were inoculated in cell cultures. SARS-CoV-2. RNA rtPCR targeted the E gene. Nasopharyngeal swab fluid or sputum sample were filtered and then inoculated in Vero E6 Cells. All samples were inoculated between 4 and 10 h after sampling and kept at + 4 °C before processing. After centrifugation they were incubated at 37 °C. They were observed daily for evidence of cytopathogenic effect. Two subcultures were performed weekly and scanned by electron microscope and then confirmed by specific RT-PCR targeting E gene. | Of the 183 samples inoculated in the studied period of time, 129 led to virus isolation. Of these 124 samples had detectable cytopathic effect between 24 and 96 h | There was a significant relationship between Ct value and culture positivity rate: samples with Ct values of 13–17 all had positive culture. Culture positivity rate decreased progressively according to Ct values to 12% at 33 Ct. No culture was obtained from samples with Ct > 34. The 5 additional isolates obtained after blind subcultures had Ct between 27 and 34, thus consistent with low viable virus load. |
| 9. | Santarpia ²⁷ | Windowsill and air, mean 7.3 samples per room. The percentage of PCR positive samples from each room was 40% -100% | 13 patients [days 5 to 9 and day 18 of isolation in a quarantine unit] | Vero E6 cells were used to culture virus from environmental samples. The cells were cultured in Dulbeccos's minimal essential medium (DMEM) supplemented with heat inactivated fetal bovine serum (10%), Penicillin/Streptomycin (10,000 IU/mL & 10,000 µg/mL) and Amphotericin B (25 µg/mL). | Possibly 2 with weak cytopathic effect | Isolates were from days 5 and 8 of occupancy of hospital/isolation rooms |
| 10. | Wölfel ²⁹ | Saliva, nasal swabs, urine, blood and stool | 9 patients [2 to 4 days] | The average virus RNA load was 6.76 × 10 ⁵ copies per the whole swab until day 5, and the maximum load was 7.11 × 10 ⁸ | Yes in respiratory samples, and indicative in stool | |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | | |
|-----|---|---|------------------------|---|------------------------------------|--|
| | | | | copies per swab. The last swab sample that tested positive was taken on day 28 after the onset of symptoms. | | |
| 11. | Kujawski ³⁰ (for The COVID-19 Investigation Team) | Nasopharyngeal (NP), oropharyngeal (OP), stool, serum and urine specimens | 9 from 9 patients | SARS-CoV-2 real-time PCR with reverse transcription (rRT-PCR) cycle threshold (Ct) values of virus isolated from the first tissue culture passage were 12.3 to 35.7 and for one patient, virus isolated from tissue culture passage 3 had a titer of 7.75×10^6 median tissue culture infectious dose per ml; these data were likely more reflective of growth in tissue culture than patient viral load. | 9 (including two non-hospitalised) | <p>Viable SARS-CoV-2 was cultured at day 9 of illness (patient 10), but was not attempted on later specimens. SARS-CoV-2 rRT-PCR Ct values of virus isolated from the first tissue culture passage were 12.3 to 35.7.</p> <p>Mean Ct values in positive specimens were 17.0 to 39.0 for NP, 22.3 to 39.7 for OP and 24.1 to 39.4 for stool. All blood and urine isolates were negative.</p> <p>Ct values of upper respiratory tract specimens were lower in the first week of illness than the second in most patients, low Ct values continued into the second and third week of illness.</p> |
| 12. | Zhang ¹⁴ | Stool | Unknown [not reported] | Vero cells were used for viral isolation from stool samples of Covid-19 patients. A 2019-nCoV strain was isolated from a stool specimen of a laboratory-confirmed COVID-19 severe pneumonia case, who experienced onset on January 16, 2020 and was sampled on February 1, 2020. The interval between sampling and onset was 15 days. The full-length genome sequence indicated that the virus had high-nucleotide similarity (99.98%) to that of the first isolated novel coronavirus isolated from Wuhan, China. In the Vero cells, viral | 1 | We do not know what influenced successful virus culture e.g. methods optimal, or concentration of virus optimal. More information needed. |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | | |
|-----|---|--|---|--|--|--|
| | | | | particles with typical morphology of a coronavirus could be observed under the electron microscope. | | |
| 13. | Xiao F, Tang M¹⁵ | Esophageal, gastric, duodenal, and rectal tissues were obtained from 1 COVID-19 patients by endoscopy. | 1 plus an unknown additional number of fecal samples from RNA-positive patients. [not reported] | Histological staining (H&E) as well as viral receptor ACE2 and viral nucleocapsid staining were performed. | 1/1 RNA-positive patient. Positive staining of viral nucleocapsid protein was visualized in the cytoplasm of gastric, duodenal, and rectum glandular epithelial cell, but not in esophageal epithelium of the 1 patient providing these tissues. Additionally, positive staining of ACE2 and SARS-CoV-2 was also observed in gastrointestinal epithelium from other patients who tested positive for SARS-CoV-2 RNA in feces, results not shown. | Total sample numbers are not reported. |
| 14. | Yao³¹ | Sputum (n=7), stool (n=3) and one nasopharyngeal sample | 11 patients admitted to hospital: 9 classified as serious or critical, 1 moderate, 1 mild symptoms [0 to 16 days] | The samples of the 11 patients involved in this study were collected during the early phase of the Covid-19 break out in China, dates ranging from 2nd of January to the 2nd of April 2020. All except one of the patients had moderate or worse symptoms. Three patients had comorbidities and one patient needed ICU treatment. Seven patients had sputum samples, one nasopharyngeal and three had stool samples | 11 samples taken up to 16 days from admission to hospital. | Cultured viruses were inoculated in Vero cells. At 8 hours post-infection there was a significant decrease in Ct value (increases in viral load) for five isolates. At 24 hours significant decreases in the Ct values for all of the viral isolates were observed. Mutations of the viruses are also reported |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | | |
|-----|--|--|------------------------------------|---|------------------------------------|---|
| | | | | <p>The samples were pre-processed by mixing with appropriate volume of MEM medium with 2% FBS, Amphotericin B, Penicillin G, Streptomycin and TPCK-trypsin. The supernatant was collected after centrifugation at 3000 rpm at room 434 temperature. Before infecting Vero-E6 cells, all collected supernatant was filtered using a 435 0.45 µm filter to remove cell debris etc.</p> <p>Vero-E6 cells were infected with 11 viral isolates and quantitatively assessed their viral load at 1, 2, 4, 8, 24, and 48 hours post-infection (PI) and their viral cytopathic effects (CPE) at 48 and 72 hours PI and examined whether the viral isolates could successfully bind to Vero-E6 243 cells as expected. Super-deep sequencing of the 11 viral isolates on the Novaseq 6000 platform was performed.</p> | | |
| 15. | Singanayagam ²² | 324 samples: nose, throat, combined nose-and throat and nasopharyngeal swabs and aspirates | 253 positive case [-10 to 60 days] | Vero E6 cells were inoculated with clinical specimens and incubated at 37 °C, 5% CO ₂ . Cells were inspected for cytopathic effect daily up to 14 days. Presence of SARS-CoV-2 was confirmed by SARSCoV-2 nucleoprotein staining by enzyme immunoassay on infected cells. | 133 (41%) samples (from 111 cases) | RT-PCR cycle threshold values correlate strongly with cultivable virus i.e. likelihood of infectiousness. Median Ct of all 324 samples was 31.15. Probability of culturing virus declines to 8% in samples with Ct > 35 and to 6% 10 days after onset and was similar in asymptomatic and symptomatic persons. Asymptomatic persons represent a source of transmissible virus but there is no difference in Ct values and culturability by age group. |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | | |
|-----|--|---|--|---|---|--|
| 16. | Perera ²¹ | 68 specimens: nasopharyngeal aspirates combined with throat swab (n=49), nasopharyngeal aspirate (n=2), nasopharyngeal swab combined with throat swab (n=3), nasopharyngeal swab (n=2), sputum (n=11) and saliva (n=1). | 35 patients, 32 with mild disease [1 to 67 days] | Specimens were tested for sgRNA with ≥ 5 log ₁₀ N gene copies per mL. The complementary DNA obtained was subjected to PCR (40 cycles). Vero E6 cells were seeded and incubated for 24 hours in a CO ₂ incubator. The culture medium was removed and 125 μ L of the clinical specimen in virus transport medium diluted and was inoculated into 2 wells. After 2 hours incubation in a CO ₂ incubator at 37°C, the plates were incubated at 37°C in a CO ₂ incubator. A sample (100 μ L) of supernatant was sampled for a quantitative real-time RT-PCR at 0 and 72 hours post inoculation. At 72 hours, cells were scraped into the supernatant and transferred onto fresh cells in 24-well plates and monitored for an additional 72 hours. A final quota of cells was collected for quantitative real-time RT-PCR. Cells were observed for cytopathic effect daily and harvested for testing if 25%–50% of cells showed a cytopathic effect. | 16/35 at a median 26 Ct | Culturable SARS CoV-2 and sub-genomic RNA (good indicator of replication) was rarely detectable beyond 8 days after onset of illness although virus RNA by RT-PCR remained for up to 70 days. |
| 17. | Brown ²⁰ | Combined viral throat and nose swab from each participant n=1,152 | Health care workers in six UK hospitals | Specimens were sent on the same day for detection of SARS-CoV-2 RNA by RT-PCR to the PHE national reference laboratory (five hospitals) or one hospital laboratory. The PHE laboratory used an Applied Biosystems 7500 FAST system targeting a conserved region of the SARS-CoV-2 open reading frame (ORF1ab) gene. The hospital laboratory used a different CE-IVD kit, targeting 3 SARS-CoV-2 genes (RdRp, E, and N). Both PCRs had internal controls. Viral culture of PHE laboratory positives was attempted in Vero E6 cells with virus detection confirmed by cytopathic effect up to 14 days post- inoculation. | SARS-CoV-2 virus was isolated from only one (5%) of nineteen cultured samples. It had a Ct value of 26.2. | Symptoms in the past month were associated with threefold increased odds of testing positive (aOR 3.46, 95%CI 1.38 to 8.67; p _L = _L 0.008). 23 of 1,152 participants tested positive (2.0%) with a median Ct of 35.70 (IQR:32.42 to 37.57). |
| 18. | L'Huillier ²³ | Nasopharyngeal | 23 (3.6%) tested | Observation of cytopathic effect on days | 12 (52% of PCR | Ct was around 28 for the |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | | |
|-----|---------------------------|--|--|---|---|--|
| | | swabs in 638 patients aged less than 16 years in Geneva Hospital | positive for SARS CoV-2 - median age of 12 years (range 7 days to 14.9 years) [1-4] | 2,4, and 6 of inoculum in Vero cells in two passages. | positive) | children whose samples grew viable viruses |
| 19. | Gniazdowski ²⁴ | 161 probably nasopharyngeal specimens | 161 cases with positive PCR [not reported] | Ct values were calculated of only one gene target per assay: the Spike (S) gene for the RealStar® SARS-CoV-2 and the nonstructural protein 101 (Nsp) 2 gene for the NeuMoDx™ SARS-CoV-2 assays. Genome sequencing was carried out. Incubation of the inoculum in VeroE6 cells cultured at 37°C was observed for 4 days for cytopathic effect and immunofluorescence used to identify viral presence | Unclear possibly 47 isolates | Positive culture was associated with Ct values of 18.8 ± 3.4 . Infectious viral shedding occurred in specimens collected up to 20 days after the first positive result in symptomatics. Mean and 184 median Ct values associated with recoverable virus were 18.8 ± 3.4 and 18.17 respectively, which was significantly lower than the mean and median Ct values that did not correlate with infectious virus recovery: 27.1 ± 5.7 and 27.5 respectively. PCR results should be interpreted alongside symptoms |
| 20. | Basile ²⁵ | 234 samples, 228 (97%) from the upper respiratory tract (sputum, naso pharyngeal swabs, bronchial lavage from 195 individuals with Covid-19. | Samples from routine laboratory tests or from patients admitted to ICU or from a physician request [mean 4.5 days, 0-18, only one day to day 18] | Probes targets for PCR included E, RdRp, N, M, and ORF1ab for samples from ICU patients and 1 to 4 E, RdRp, N and Orf1ab for all other samples. After stabilization at 4 degrees centigrade samples were inoculated into Vero E6 cells and incubated at 37°C in 5% CO2 for 5 days (day 0 to 4). Cultures were observed daily for cytopathic effect (CPE). CPE when it occurred took place between days 2 and 4. Day 4 was chosen for terminal sampling. | Culture positivity rate was 56 (24%) and significantly more likely positive in ICU patients compared with other inpatients or outpatients and significantly more likely positive in samples from inpatients | The highest Ct value with a successful culture was 32 (N gene target). A Ct cut-off of ≥ 37 was not indicative of viable virus |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| Serial | Study | Samples (source) | Samples (n) [SST] | Culture methods | Culture Positive | Additional notes |
|--------|-------------------------|--|--|--|--|--|
| 21. | Zhou 2020 ²⁸ | 218 surface samples 31 air samples | 7 areas of large London hospital | RT-PCR with primers and probes for the envelope (E) gene. Duplicate PCR was carried out and samples were considered positive if both duplicates had Ct < 40.4, or suspect if one of the two have Ct < 40.4 (equivalent to one genome copy. For culture Vero E6 and Caco2 cells were used from air and environmental samples using a method adapted from one previously used to culture influenza virus. On day 0 and after 5-7 days, cell supernatants were collected, and RT-qPCR to detect SARS-CoV-2 performed as described above. Samples with at least one log increase in copy numbers for the E gene (reduced Ct values relative to the original samples) after 5-7 days propagation in cells compared with the starting value were considered positive by viral culture. | No cultures were positive | The pre-defined cycle threshold cut off was too high |
| 22. | Kim 2020 ⁴⁷ | Unclear. Possibly 323 serum 247 urine and 129 stool samples | 74 COVID-19 hospital patients | RT-PCR was performed on the target genes were E and RdRp. Cell culture was performed in a Level III facility by inoculum into CaCo-2 cell line after stabilisation at 4C and harvested after 5 days and the supernatant after centrifugation was re-inoculated for another 5 days and assessed with RT-PCR. | No viral growth was detected in any specimen despite a positive RT-PCR very soon after admission | |
| 23. | Lu 2020 ³⁴ | 87 cases testing “re-positive” at RT-PCR 137 swabs (51 nasopharyngeal, 18 throat and 68 anal) | 619 hospital discharges of which tested positive after discharge | 137 swabs and 59 serum samples from 70 “repositive” cases to assess the immunological and virologic characteristics of the SARS-CoV-2 “repositive” cases. From 23 January, hospital discharges followed a strict isolation protocol living (for example) in | No cultures were positive | “Re-positive” cases are unlikely to be infectious as no intact RNA single helix was detected or viral isolated grew. Prolonged detection of |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | | |
|-----|-------------------------|---|--|---|---|---|
| | | | | <p>single dedicated hotel rooms and went home only when nucleic acid tests were negative on both respiratory tract and digestive tract samples. Samples (nasopharyngeal, throat and anal swabs), were collected for RT-PCR diagnosis at 7 and 14 days after discharge. Culture was carried out by inoculating Vero E6 cells with patient sample. CPE were observed daily at 7 days with a second round of passage. RT-PCR diagnosis was carried out on RNA using three RT-PCR kits to conduct nucleic acid testing, in an attempt to avoid false negatives. Ct varied from 29 to 39 depending on gene and kit</p> | | <p>viral RNA is a challenge for public health interventions targeted at isolating infectious cases. "Re-positive" discharged cases are caused by intermittent shedding of cells containing remnant RNA.</p> |
| 24. | Andersson ³⁵ | <p>20 RT-PCR positive serum samples, selected at random from a Covid-19 sample bank, representing samples from 12 individual patients (four individuals were represented at two timepoints), collected at 3 to 20 days following onset of symptoms.</p> | <p>20 serum samples from 12 hospitalised Covid-19 patients</p> | <p>Samples VC01-20 were provided blinded for viral culture experiments. 50 µL aliquots of samples VC1-VC20 were separately added to 2.4 x 10⁵ Vero E6 cells in 24-well plates. Cells were propagated in DMEM supplemented with 10% FBS. Virus growth assays were done in DMEM supplemented with 1% FBS, glutamine and penicillin/streptomycin, according to published methods. In parallel, wells of the same number of cells were cultured in triplicate without virus challenge but with 50 µL control serum (VC21), or in duplicate with a stock of Victoria/01/2020 SARS-CoV-2 passage 4 (Oxford) at calculated ten-fold serial dilutions per well of 78, 7.8, 0.78 and 0.078 plaque forming units (pfu) in 50</p> | <p>0 / 20 these serum samples produced positive viral culture</p> | <p>Serum samples.</p> |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | | |
|-----|--------------------------|---|-------------|---|-----------------------------|--|
| | | | | <p> μL of control serum (VC21). Wells were observed daily for cytopathic effects (CPE), and 50 L samples were taken for vRNA extraction on day 3 post-challenge. On day 4, 50 L aliquots of supernatants from cells challenged with VC01-20 were “blind passaged” to fresh cells, and the remaining supernatants were harvested and stored separately at -80C for future analysis. After a further 3 days, CPE was recorded, if any, for second passage cultures. </p> | | |
| 25. | Korean CDC ²⁶ | Respiratory swab samples for individuals testing positive after having previously tested positive, then negative. | 108 samples | Methods not reported | 0 / 108 respiratory samples | This report does not give the laboratory methods used. |

Table 1. Characteristics of included studies. Key: STT = symptom onset to test date.

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| Study | Description of methods and sufficient detail to replicate | Sample sources clear | Analysis & reporting appropriate | Is bias dealt with | Applicability |
|------------------------------|---|----------------------|----------------------------------|--------------------|---------------|
| Bullard 2020 ⁴ | Yes | Yes | yes | unclear | unclear |
| Santarpia 2020 ²⁷ | Yes | Yes | yes | unclear | unclear |
| Wölfel 2020 ²⁹ | Yes | Yes | yes | unclear | unclear |
| Huang 2020 ⁵ | yes | Yes | yes | unclear | unclear |
| Wang W ¹² 2020 | No | Yes | yes | no | unclear |
| Zhang Y 2020 ¹⁴ | Partly | Yes | yes | no | unclear |
| Xiao 2020b ¹⁵ | No | Yes | yes | no | unclear |
| Qian Q 2020 ¹⁷ | Yes | Yes | yes | unclear | unclear |
| Arons 2020 ¹⁸ | Yes | Yes | yes | yes | unclear |
| Xiao F 2020 ¹³ | Yes | Yes | yes | no | unclear |
| Kujawski 2020 ³⁰ | Yes | Yes | yes | unclear | unclear |
| Jeong 2020 ¹¹ | Yes | Yes | yes | no | unclear |
| La Scola 2020 ¹⁹ | Yes | Yes | yes | unclear | unclear |
| Yoa H 2020 ³¹ | Yes | Yes | yes | unclear | unclear |
| Singanayagam ²² | Yes | No | Yes | unclear | unclear |
| Perera ²¹ | Yes | Yes | Yes | unclear | unclear |
| Brown ²⁰ | Yes | Yes | Yes | Unclear | unclear |
| Gniazdowski ²⁴ | Yes | Yes | Yes | Unclear | unclear |
| Basile ²⁵ | Yes | Yes | Yes | Unclear | unclear |
| L'Huillier ²³ | Yes | Yes | Yes | Unclear | unclear |
| Zhou 2020 ²⁸ | Yes | Yes | Yes | Unclear | unclear |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | |
|--------------------------|-----|--------|--------|---------|---------|
| Kim ⁴⁷ | No | No | No | Unclear | Unclear |
| Lu ³⁴ | Yes | Yes | Yes | Partly | Yes |
| Andersson ³⁵ | Yes | Yes | Yes | Partly | Yes |
| Korean CDC ²⁶ | No | Partly | Partly | No | Unclear |

Table 2. Quality of included studies

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Table 3. Duration of viral shedding in the included studies.

| Study | Duration of viral shedding as assessed by PCR for SARS-CoV-2 RNA | Range of duration | Median of duration | Notes on clinical course |
|--------------------------------------|--|-------------------|--------------------|---|
| Bullard ⁴ | Day 0 to day 7 at least. | NR | NR | SARS-CoV-2 Vero cell infectivity of respiratory samples from SARS-CoV-2 positive individuals was only observed for RT-PCR Ct < 24 and symptom onset to test of < 8 days. |
| Jeong ¹¹ | At least 8 days to at least 30 days | NR | NR | <p>5 positive-PCR patients, day 8 to day 30 after symptom onset.</p> <p>At the time of sampling, patients 1, 2, 3, and 5 were on days 8, 13, 11, and 30 of illness, respectively, and their clinical symptoms had resolved completely.</p> <p>Patient 4 was on day 15 of illness with a ventilator and extracorporeal membrane oxygenation support.</p> <p>All clinical specimens collected from the five patients were positive for the SARS-CoV-2 spike gene by qPCR, even though four of the patients no longer displayed clinical symptoms.</p> |
| Qian ¹⁷ | SARS-CoV-2 RNA detected day 10 to between day 18 and day 35 after symptom onset. | | | <p>Covid-19 symptoms began on day 3 after surgery on day 0. SARS-CoV-2 PCR test done on day 7 after surgery.</p> <p>PCR on day 14 and day 18 post-surgery were positive.</p> <p>PCR on day 37 and day 38 after surgery were negative.</p> |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | |
|---|---|--------------|----|---|
| | | | | <p>Patient was discharged on day 41 after surgery following the 2 sequential negative PCR tests plus absence of clinical symptoms and radiological abnormalities.</p> <p>Fecal samples day 35 after discharge were negative.</p> |
| Xiao F, Sun J ¹³ | Day 7 after symptom onset to at least day 28. | | | <p>1 patient. SARS-CoV-2 RNA PCR positive at day 7 after symptom onset.</p> <p>Patient died two weeks after final sample.</p> |
| Wölfel ²⁹ | Up to day 28 after onset of symptoms. | NR | NR | <p>9 cases.</p> <p>All swabs taken between day 1 and day 5 were positive by PCR.</p> <p>Virus could not be isolated from samples taken after day 8 even among cases with ongoing high viral loads of approximately 105 RNA copies/mL</p> |
| Kujawski ³⁰ (for The COVID-19 Investigation Team) | Duration of SARS-CoV-2 detection by RT-PCR was 7 to 22 days | 7 to 22 days | | <p>First 12 identified patients in the US. Respiratory specimens collected between illness days 1 to 9 (median, day 4)</p> <p>All patients had SARS-CoV-2 RNA detected in respiratory specimens, typically for 2 to 3 weeks after illness onset.</p> <p>Mean duration of fever was 9 days. Two patients received a short course of corticosteroids.</p> |
| Xiao ¹⁵ , Tang M | 1 to 12 days (stool samples) | 1 to 12 days | NR | <p>Positive stool results duration ranged from 1 to 12 days.</p> |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | |
|----------------------------|--|---|----|--|
| | Duration of detection of SARS-CoV-2 respiratory samples not reported. | | | 17 (23%) patients continued to have positive results in stool after showing negative results in respiratory samples. |
| Singanayagam ²² | At least day 20 post symptom onset, upper respiratory tract swabs PCR | NR | NR | Median duration of virus shedding as measured by <u>viral culture</u> was 4 days (IQR: 1 to 8; range: -13 to 12, with symptom onset dates based on symptom recall) |
| Perera ²¹ | >30 days in 10 patients | NR | NR | |
| Brown ²⁰ | NR | NR | NR | |
| Gniazdowski ²⁴ | Up to 22 days in subset of 29 patients | 1-22 days | NR | Ct values reported in aggregate and for subset of 20 patients but retrospective nature of specimens precluded details description |
| Lu ³⁴ | Not reported in paper or suppl material (no linking of patient number with type of sample but may be available from the authors) | | | |
| Andersson ³⁵ | Not included in this paper | | | |
| Korean CDC ²⁶ | Time to retesting positive via PCR is reported, among this specific group of individuals who retested positive by PCR | On average, it took 44.9 days (range: 8 to 82 days) from initial symptom onset date to testing positive after discharge. (Based on 226 cases symptomatic at the time of | | This may indicate an overall duration of viral shedding, indicating that shedding of RNA may detected over a long period of time and inconsistently. This data may not be comparable with information from studies specifically observing duration of viral shedding as an outcome. |

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | |
|--|--|-----------------------|--|--|
| | | initial confirmation) | | |
|--|--|-----------------------|--|--|

Viral cultures for COVID-19 infectivity assessment – a systematic review
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Table 4: Relationship of PCR Cycle threshold and Log¹⁰ copies to Positive Viral Culture

| Study | Sample | | | | Cycle Threshold | | | Log ¹⁰ copies | | | ORs for Viral Culture |
|---|--|--------------------------|---------------|-----------------------------------|---------------------------------|--------------------------------|---|---|---|-------------------------------|--|
| | RT-PCR SARS-CoV-2 positive samples (n) | Viral Culture growth (n) | No growth (n) | Gene fragment sampled on PCR Test | Positive culture Ct value | Negative culture Ct Value | No growth in samples based on Ct | Log ¹⁰ copies positive culture (unless otherwise stated) | Log ¹⁰ copies negative culture | No growth based on log copies | |
| Bullard J 2020⁴ | 90 | 26 | 64 | E gene | 17 [16-18] | 27 [22-33] | Ct > 24 | | | | OR 0.64 (95%CI 0.49 to 0.84, p<0.001) for every one unit increase in Ct. |
| Huang 2020⁵ | 60 | 23 | 34 | Nsp 12 | Mean 23.9 ± SEM 0.78 | Mean 29.26 ± SEM 0.78 | Ct >31.47 | mean 7.37 ± SEM 0.20 | Mean 5.98 ± SEM 0.18 | | |
| | | 23 | 37 | E | Mean 22.39 ± SEM 0.75 | Mean 28.92 ± SEM 0.65 | Ct >31.46 | mean 8.21 ± SEM 0.18 | Mean 6.62 ± SEM 0.16 | | |
| | | 21 | 31 | N | Mean 27.29 ± SEM 0.77 | Mean 31.49 ± SEM 0.59 | Ct >35.2 | mean 7.87 ± SEM 0.21 | Mean 6.70 ± SEM 0.17 | | |
| La Scola 2020¹⁹ | 611 | 129 | 482 | | | | Ct ≥ 34 | | | | |
| Brown CS²⁰ | 23 | 1 | 22 | RdRp, E, and N | 26.16 | 35.16 ± SEM 0.63 | Ct >26.2 | | | | |
| Perera RAPM 2020²¹ | 68 | 16 | 52 | N | | | | 7.5 ² | 3.8 | <5.0 | |
| Singanavagam 2020²² | 324 | 133 | 191 | Unclear | | | Ct > 35 probability of no growth was 8.3% (95% CI: 2.8%–18.4%) ¹ | | | | OR 0.67 for each unit increase in Ct value (95% CI: 0.58–0.77) |
| Wölfel 2020²⁹ | 45 | 9 | 36 | E, Subgenomic mRNA. | | | | | | | |
| L'Huillier 2020²³ | 23 ⁴ | 12 | 11 | | | | | Mean 7.9×10 ⁸ IQR 4.7×10 ⁶ - 1.0×10 ⁹ | Mean 5.4×10 ⁷ IQR 4.2×10 ³ - 1.8×10 ⁶ | | |
| Gniazdowski R 2020²⁴ | 132 | 47 | 85 | S, Nsp 2 | Mean 12.8 ± 3.4 Median 18.17 | Mean 27.1 ± 5.7 Median 27.5 | Ct ≥ 23 yielded 8.5% of virus isolates | | | | |
| Basile K 2020²⁵ | 234 | 56 | 178 | E, RdRp, N, M, and | 25.01 | 27.75 | Ct >32 with the N gene target ³ | | | | |

Viral cultures for COVID-19 infectivity assessment – a systematic review
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

| | | | | | | | | | | | |
|--|--|--|--|--------------------------|--|--|--|--|--|--|--|
| | | | | ORF1ab for ICU patients; | | | | | | | |
|--|--|--|--|--------------------------|--|--|--|--|--|--|--|

- 1 All above CT (n=5) 35 were symptomatic
2. Of the 16 culture positive specimens, 15 (94%) had viral RNA load >6 log₁₀ copies/mL (p<0.01). All of them were collected within the first 8 days of illness
3. no CPE visualised but a decrease in Ct values between the Ct of the original clinical sample PCR (Ct_{sample}) and the terminal culture (day four) supernatant PCR (Ct_{culture}) of ≥3 (equivalent to a 1 log increase in virus quantity) i.e. Ct_{sample} – Ct_{culture} ≥3 = culture positive. The authors hypothesized that a Ct_{sample} minus Ct_{culture} <3 was due to residual inoculated clinical sample and not replicating virus.
- 4.23 SARS-CoV-2–infected children